A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with
or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess
the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with
...
Age: 2 - 17 years
Gender: All
A Long-term Extension Study of Ustekinumab in Pediatric Participants
The purpose of this study is to collect long-term safety data of subcutaneous (SC)
ustekinumab
Age: 2 - 17 years
Gender: All
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants
with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of
PsA.
Age: 18 years - 66+
Gender: All
An open-label pilot study to investigate the efficacy of apremilast in the treatment of central centrifugal cicatricial alopecia (CCCA)
"The purpose of this study is to see if the use of apremilast has an effect on the symptoms and progression of central centrifugal cicatricial alopecia (CCCA). Apremilast is an oral PDE4 inhibitor that has anti-inflammatory properties. It inhibits several substances inv...
Age: 18 years - 66+
Gender: Female
Psoriasis Longitudinal Assessment and Registry (PSOLAR)
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and
guselkumab in patients with plaque psoriasis, and other all forms of psoriasis (such as
plaque psoriasis and psoriatic arthritis occurring together). The registry study will tr...
Age: 18 - 99 years
Gender: All
Psoriasis Longitudinal Assessment and Registry
The purpose of this study is to further evaluate the safety of infliximab, ustekinumab, and
guselkumab in patients with plaque and other forms of psoriasis. The study also includes
patients receiving other therapies, such as non-biologic and other biologic agents. T...
Age: 18 - 99 years
Gender: All